---
input_text: "Therapeutic hypothermia for pediatric refractory status epilepticus May
  Ameliorate post-status epilepticus epilepsy. BACKGROUND: To compare the clinical
  characteristics and outcomes of pediatric patients with refractory status epilepticus
  (RSE) and super-refractory status epilepticus (SRSE) who received therapeutic hypothermia
  (TH) plus anticonvulsants or anticonvulsants alone. METHODS: Two-medical referral
  centers, retrospective cohort study. Pediatric Intensive Care Unit (PICU) at Taoyuan
  Chang Gung Children's hospital and Kaohsiung Chang Gung Memorial Hospital. We reviewed
  the medical records of 23 patients with RSE/SRSE who were admitted to PICU from
  January 2014 to December 2017. Of these, 11 patients received TH (TH group) and
  12 patients did not (control group). RESULTS: The selective endpoints were RSE/SRSE
  duration, length of PICU stay, and Glasgow Outcome Scale (GOS) score. We applied
  TH using the Artic Sun  temperature management system (target temperature, 34-35\
  \  C; duration, 48-72 h). Of the 11 patients who received TH, 7 had febrile infection-related
  epilepsy syndrome (FIRSE), one had Dravet syndrome, and three had traumatic brain
  injury. The TH group had significantly shortern seizure durations than did the control
  group (hrs; median (IQR) 24(40) vs. 96(90), p < 0.05). Two patients in the TH group
  died of pulmonary embolism and extreme brain edema. The length of PICU stay was
  similar between the groups (days; median (IQR) 30(42) v.s 30.5(30.25)). The TH group
  had significantly better long-term outcomes than did the control group (GOS score,
  median (IQR) 4(2) v.s 3 (0.75), p = 0.01*). The TH group had a significantly lower
  incidence of later chronic refractory epilepsy than did the control group (TH v.s
  non-TH, 5/11 (45%) v.s. 12/12(100%), p < 0.01). CONCLUSIONS: TH effectively reduced
  the seizure burden in patients with RSE/SRSE. Our findings support that for patients
  with RSE/SRSE, TH shortens the seizure duration, ultimately reducing the occurrence
  of post-status epilepticus epilepsy and improving patients' long-term survival."
raw_completion_output: |-
  primary_disease: Refractory status epilepticus (RSE)/Super-refractory status epilepticus (SRSE)

  medical_actions: Therapeutic hypothermia (TH);Anticonvulsants

  symptoms: Seizure;Post-status epilepticus epilepsy;Febrile infection-related epilepsy syndrome (FIRSE);Dravet syndrome;Traumatic brain injury

  chemicals: 

  action_annotation_relationships: Therapeutic hypothermia (TH) TREATS Seizure IN Refractory status epilepticus (RSE)/Super-refractory status epilepticus (SRSE);Anticonvulsants TREATS Seizure IN Refractory status epilepticus (RSE)/Super-refractory status epilepticus (SRSE);Therapeutic hypothermia (TH) PREVENTS Post-status epilepticus epilepsy IN Refractory status epilepticus (RSE)/Super-refractory status epilepticus (SRSE)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Therapeutic hypothermia (TH) PREVENTS Post-status epilepticus epilepsy IN Refractory status epilepticus (RSE)/Super-refractory status epilepticus (SRSE)

  ===

extracted_object:
  primary_disease: Refractory status epilepticus (RSE)/Super-refractory status epilepticus
    (SRSE)
  medical_actions:
    - Therapeutic hypothermia (TH)
    - Anticonvulsants
  symptoms:
    - HP:0001250
    - Post-status epilepticus epilepsy
    - Febrile infection-related epilepsy syndrome (FIRSE)
    - Dravet syndrome
    - Traumatic brain injury
  action_annotation_relationships:
    - subject: <Therapeutic hypothermia>
      predicate: <TREATS>
      object: <Seizure>
      qualifier: <Refractory status epilepticus/Super-refractory status epilepticus>
      subject_extension: <Therapeutic hypothermia>
    - subject: Anticonvulsants
      predicate: TREATS
      object: HP:0001250
      qualifier: Refractory status epilepticus (RSE)/Super-refractory status epilepticus
        (SRSE)
      subject_extension: CHEBI:35623
    - subject: <Therapeutic hypothermia>
      predicate: <PREVENTS>
      object: <Post-status epilepticus epilepsy>
      qualifier: <Refractory status epilepticus/Super-refractory status epilepticus>
      subject_extension: <Therapeutic hypothermia>
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
